IP Library › Granted Patent US 11,560,404
Granted Patent B2
US 11,560,404 · App. 17/224,353 · Granted Jan 24, 2023

Crystalline dipeptides useful in the synthesis of elamipretide

Inventors: Scott M. Duncan (Bedford, MA); Martin P. Redmon (Boston, MA)
Assignee: Stealth BioTherapeutics Inc.
C07K5/06095C07C237/20C07K5/06086C07B2200/13
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,560,404
App. No.
17/224,353
Granted
Jan 24, 2023
Kind
B2
Abstract

Disclosed are crystalline forms of L-Lys(Boc)-Phe-NH 2 and Boc-D-Arg-DMT. The crystalline forms may be used in the synthesis of elamipretide.

Claims (281)

1. A crystalline form of Compound (I),

wherein said crystalline form has characteristic peaks in its XRPD pattern at values of two theta as described in Table 1:

TABLE 1

Net

Gross

Rel.

Angle

d value

Intensity

Intensity

intensity

4.704

18.77211

9559

11528

100.0%

5.230

16.88407

624

2301

6.5%

5.648

15.63394

862

2340

9.0%

6.200

14.24402

7663

8912

80.2%

6.650

13.28067

394

1456

4.1%

7.056

12.51772

508

1400

5.3%

7.709

11.45860

1161

1869

12.1%

8.553

10.33046

2135

2771

22.3%

9.402

9.39869

2473

3073

25.9%

9.922

8.90729

2627

3206

27.5%

10.303

8.57920

1435

1997

15.0%

11.292

7.82975

3301

3848

34.5%

11.755

7.52244

1985

2530

20.8%

12.205

7.24594

2827

3370

29.6%

12.452

7.10259

4581

5123

47.9%

12.655

6.98916

2764

3305

28.9%

13.270

6.66655

4117

4655

43.1%

13.778

6.42221

795

1330

8.3%

14.133

6.26164

333

866

3.5%

14.462

6.11961

882

1413

9.2%

14.957

5.91833

3726

4255

39.0%

15.756

5.61997

7404

7928

77.5%

16.263

5.44580

2360

2881

24.7%

16.504

5.36683

5366

5885

56.1%

16.961

5.22337

2930

3447

30.7%

17.107

5.17917

2585

3100

27.0%

17.658

5.01859

3807

4320

39.8%

17.956

4.93596

4360

4871

45.6%

18.210

4.86777

4451

4960

46.6%

18.832

4.70852

8963

9468

93.8%

19.561

4.53460

3331

3830

34.8%

19.802

4.47996

7877

8375

82.4%

20.265

4.37865

1989

2483

20.8%

20.715

4.28449

1746

2237

18.3%

21.514

4.12715

1756

2241

18.4%

21.958

4.04471

4087

4568

42.7%

22.807

3.89590

3856

4331

40.3%

23.398

3.79891

779

1248

8.1%

23.660

3.75740

835

1303

8.7%

24.306

3.65896

726

1188

7.6%

25.050

3.55198

2158

2614

22.6%

25.462

3.49548

764

1217

8.0%

25.709

3.46234

1227

1677

12.8%

26.016

3.42222

714

1161

7.5%

26.319

3.38357

521

966

5.5%

26.713

3.33445

662

1103

6.9%

27.411

3.25119

709

1143

7.4%

28.356

3.14493

831

1256

8.7%

28.808

3.09664

340

761

3.6%

30.662

2.91341

740

1142

7.7%

31.492

2.83854

649

1041

6.8%

35.876

2.50109

376

740

3.9%

36.369

2.46832

362

723

3.8%.

2. A crystalline form of Compound (I),

wherein said crystalline form has characteristic peaks in its XRPD pattern as shown in FIG. 1 .

3. A crystalline form of Compound (I),

wherein said crystalline form has characteristic peaks in its XRPD pattern at values of two theta (° 20) of: 4.7, 6.2, 12.4, 15.8, 16.5, 18.0, 18.2, 18.8, and 19.8.

4. The crystalline form of claim 3 , wherein said crystalline form has characteristic peaks in its XRPD pattern at values of two theta (° 20) of: 4.7, 6.2, 11.3, 12.4, 13.3, 15.0, 15.8, 16.5, 17.0, 17.7, 18.0, 18.2, 18.8, 19.8, 22.0, and 22.8.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 27, 2022
From: DUNCAN, SCOTT M.; REDMON, MARTIN P.
To: STEALTH BIOTHERAPEUTICS CORP.
Reel/Frame 059751/0428 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 27, 2022
From: STEALTH BIOTHERAPEUTICS CORP.
To: STEALTH BIOTHERAPEUTICS INC.
Reel/Frame 059806/0537 →
Continuity (3)
Division 16485369
Provisional Application 62651430 · Apr 2, 2018
Related Publication 20210292274A1 · Sep 23, 2021